Skip to main content
Figure 4 | Journal of Nanobiotechnology

Figure 4

From: Detection of residual rifampicin in urine via fluorescence quenching of gold nanoclusters on paper

Figure 4

a Fluorescence emission spectra of BSA-Au NCs (0.1× dilution) in the presence of primary TB drugs (100 µM each in the final concentration). At 640 nm (emission wavelength): BSA-Au NCs (fluorescence intensity = 123.74 ± 1.56), NCs + rifampicin (83 µg/mL) (13.67 ± 0.33), NCs + pyrazinamide (12.3 µg/mL) (121.95 ± 0.69), NCs + ethambutol (27.7 µg/mL) (114.27 ± 1.28) and NCs + izoniazid (13.7 µg/mL) (127 ± 0.69) (each data point represents the average of three separate studies (n = 3), and the error bars denote the standard error of measurements within each experiment). b Comparison of the normalized decrease in fluorescence intensity of BSA-Au NCs (0.1× dilution) in the presence of primary TB drugs (100 µM each in final concentration). At 640 nm (emission wavelength): normalized quenching of NCs + rifampicin [(F0 − F)/F0 ~ 0.89 ± 0.006], NCs + pyrazinamide [0.013 ± 0.005], NCs + ethambutol [0.065 ± 0.008] and NCs + izoniazid [0.028 ± 0.007] (each data point represents the average of three separate studies (n = 3), and the error bars denote the standard error of measurements within each experiment). [In this work, (F0 − F)/F0 = 1 indicates complete quenching and (F0 − F)/F0 = 0 indicates no quenching]. The excitation wavelength was set at 480 nm, and the emission wavelength was 640 nm.

Back to article page